G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Smilelove offers clear aligner treatments direct-to-consumer: no expensive appoint...
Smilelove offers clear aligner treatments direc...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Meridian is a fully integrated life science company that develops, manufactures, m...
Meridian is a fully integrated life science com...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
Aldeyra Therapeutics is a biotechnology company devoted to developing and commerci...
Aldeyra Therapeutics is a biotechnology company...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.